Profarma - 3Q16 earnings release
-
Upload
profarma -
Category
Investor Relations
-
view
48 -
download
0
Transcript of Profarma - 3Q16 earnings release
![Page 1: Profarma - 3Q16 earnings release](https://reader031.fdocuments.us/reader031/viewer/2022030212/58a0ce821a28ab6d018b6829/html5/thumbnails/1.jpg)
NOVEMBER 9, 2016
![Page 2: Profarma - 3Q16 earnings release](https://reader031.fdocuments.us/reader031/viewer/2022030212/58a0ce821a28ab6d018b6829/html5/thumbnails/2.jpg)
2
• The only Brazil’s mixed market player that features exposure and expansion
capacity in the segments of Retail, Hospital & Specialties and Distribution;
• Strategic partnership with AmerisourceBergen, the world’s largest player in the
pharmaceutical specialties, resulting in the creation of the company Profarma
Specialty since 2014;
• The Company carried out five acquisitions between 2012-2016, including its
entry into the Retail pharmaceutical segment, and the attainment of a market
position as 6th largest player within this segment in the country;
• Proven capacity to integrate acquisitions, combining all group companies in the
SAP plataform, BI Cognos and Hyperion.
![Page 3: Profarma - 3Q16 earnings release](https://reader031.fdocuments.us/reader031/viewer/2022030212/58a0ce821a28ab6d018b6829/html5/thumbnails/3.jpg)
3
![Page 4: Profarma - 3Q16 earnings release](https://reader031.fdocuments.us/reader031/viewer/2022030212/58a0ce821a28ab6d018b6829/html5/thumbnails/4.jpg)
Specialties(*)
3Q15 3Q16
Retail(**)
3Q15 3Q16
Consolidated (*)(**)
3Q15 3Q16
Pharmaceutical
Distribution
3Q15 3Q16
4
Gross Revenues
Gross Profit
SGA
Ebitda
(**) pro forma figures: 100% of revenues from Tamoio in 3Q15.
(*) pro forma figures: 100% of revenues from Specialties (3Q15 and 3Q16).
201.4
22.3
16.4
5.6
241.5
23.5
20.0
1.9
191.0
55.8
51.5
2.5
198.1
60.0
51.2
7.1
1,311.2
162.0
132.4
29.1
1,367.3
177.7
140.0
38.9
1,010.4
83.9
64.5
21.2
1,040.6
94.2
68.7
30.0
![Page 5: Profarma - 3Q16 earnings release](https://reader031.fdocuments.us/reader031/viewer/2022030212/58a0ce821a28ab6d018b6829/html5/thumbnails/5.jpg)
![Page 6: Profarma - 3Q16 earnings release](https://reader031.fdocuments.us/reader031/viewer/2022030212/58a0ce821a28ab6d018b6829/html5/thumbnails/6.jpg)
Specialties
6
Gross Revenues Evolution(R$ million)
Pharmaceutical Distribution
Sales increased by 3.0% year-over-
year
Sales increased by 19.9% in
comparison with 3Q15
Sales increased by 3.7% year-over-
year
Accounting Consolidated Gross Revenues
pro forma Consolidated Gross Revenues: 3Q15 – 100% of Tamoio
and Specialties / 2Q16 and 3Q16 – 100% of Specialties
Retail
3Q15 2Q16 3Q16
1,072.2
238.9
1,311.2
1,149.6
207.6
1,357.3
1,162.8
204,5
1,367.3
0.7%
4.3%
![Page 7: Profarma - 3Q16 earnings release](https://reader031.fdocuments.us/reader031/viewer/2022030212/58a0ce821a28ab6d018b6829/html5/thumbnails/7.jpg)
Pharmaceutical Distribution Specialties(**) Retail
7
Gross Revenues Evolution(R$ million)
Accounting Gross Revenues
pro forma additional Gross
Revenues
(*) pro forma figures: 100% of Tamoio and Drogasmil / Farmalife
(**) pro forma figures: 100% of Specialties
3Q15 2Q16 3Q16 3Q15 2Q16 3Q16 3Q15(*) 2Q16 3Q16
1,010.4 1,003.2
3.7%
3.0%
201.4
246.5 241.5
-2.0%
19.9%
78.6
3.7%
112.4
191.0
198.1
-3.2%
1,040.6 204.8
![Page 8: Profarma - 3Q16 earnings release](https://reader031.fdocuments.us/reader031/viewer/2022030212/58a0ce821a28ab6d018b6829/html5/thumbnails/8.jpg)
8
Gross Profit(R$ million and % Net Revenues)
3Q163Q15 2Q16 3Q163Q15 2Q16
(*) pro forma data: 3Q15 – 100% of Tamoio and Specialties / 2Q16 and 3Q16 – 100% of Specialties
pro forma(*)
11.6%
108.2
17.8%
177.6
15.2%
154.1
17.6%14.0%
162.0
208.4
14.9%
177.7
![Page 9: Profarma - 3Q16 earnings release](https://reader031.fdocuments.us/reader031/viewer/2022030212/58a0ce821a28ab6d018b6829/html5/thumbnails/9.jpg)
9
Operating Expenses – SGA(R$ $ million and % Net Revenues)
3Q163Q15 2Q16 3Q163Q15 2Q16
(*) pro forma data: 3Q15 – 100% of Tamoio and Specialties / 2Q16 and 3Q16 – 100% of Specialties
11.5%
132.4
11.8%
139.9
11.7%
140.0
9.6%
12.0% 11.8%
90.2119.6 120.0
pro forma(*)
![Page 10: Profarma - 3Q16 earnings release](https://reader031.fdocuments.us/reader031/viewer/2022030212/58a0ce821a28ab6d018b6829/html5/thumbnails/10.jpg)
10
Adjusted EBITDA and Adjusted EBITDA Margin(R$ million and % Net Revenues)
3Q163Q15 2Q16 3Q163Q15 2Q16
(*) pro forma data: 3Q15 – 100% of Tamoio and Specialties / 2Q16 and 3Q16 – 100% of Specialties
2.2%
21.0
5.4%
54.1
3.5%
35.4
2.5%
29.1
5.1%
60.2
3.3%
38.9
pro forma(*)
-34.7%
68.6%
-35.3%
33.8%
![Page 11: Profarma - 3Q16 earnings release](https://reader031.fdocuments.us/reader031/viewer/2022030212/58a0ce821a28ab6d018b6829/html5/thumbnails/11.jpg)
11
Net Profit(R$ million and % Net Revenues)
Net Profit
Adjusted Net Profit
pro forma Net Profit
pro forma Adjusted Net Profit
(*) pro forma data: 3Q15 – 100% of Tamoio and Specialties / 2Q16 and 3Q16 – 100% of Specialties
8.5
3Q15
(4.4)
-0.4% 0.6%-1.0%
2Q16
7.5
(12.2)(6.4)
3Q16
-0.7%0.8%
-0.9%
(9.5)
2Q16
(4.9)
1.0
16.0
-0.5%1.6%
0.1%
(2.9)
15.0
(0.1)
-0.3%1.3%
0.0%
3Q15 3Q16
pro forma(*)
![Page 12: Profarma - 3Q16 earnings release](https://reader031.fdocuments.us/reader031/viewer/2022030212/58a0ce821a28ab6d018b6829/html5/thumbnails/12.jpg)
Cash Flow(R$ million)
* Average
(1) Average of Gross Revenues in the Quarter
(2) Average of COGS in the Quarter
(3) Average of COGS in the Quarter
(4) The account was based on the average gross sale and CGS, excluding Specialties
division and Tamio’s chain
(5) The account was based on the average gross sale and CGS, excluding Specialties
division
Cash Cycle(Days)
Cash Flow Generated /
Used) in Operating Activities
Internal Cash Generation
Operating Assets Variation
Cash Flow (Used)
in Investing Activities
Cash Flow Generated /
(Used) by Financing Activities
Net Increase /
(Decrease) in Cash
12
Consolidated
Pro forma
Cash Cycle *
Accounts Receivable¹
Inventories²
Accounts Payable³
Consolidated Pharma PFS. Retail
3Q16 3Q15 3Q1652Q1653Q154 3Q163Q163Q16
69.6
19.8
49.8
(10.2)
(30.9)
28.4
58.2
18.5
39.7
(5.8)
(45.0)
7.4
40.2
63.1
52.1
51.235.4
44.5
54.1
63.2
44.3
71.2
60.5
55.2
15.3
63.8
39.4
39.746.3
56.7
42.3
52.7
46.7
46.3
56.4
55.9
![Page 13: Profarma - 3Q16 earnings release](https://reader031.fdocuments.us/reader031/viewer/2022030212/58a0ce821a28ab6d018b6829/html5/thumbnails/13.jpg)
13
Capex(R$ million)
Indebtedness: Net Debt and Net Debt /
EBITDA (R$ million)
Capex
3Q16OtherIT
Machinery and
Equipment3Q15 2Q16 3Q16
10.92.0
1.4
7.4
301.1
428.4
397.8
4.0x 3.8x
3.1x
![Page 14: Profarma - 3Q16 earnings release](https://reader031.fdocuments.us/reader031/viewer/2022030212/58a0ce821a28ab6d018b6829/html5/thumbnails/14.jpg)
![Page 15: Profarma - 3Q16 earnings release](https://reader031.fdocuments.us/reader031/viewer/2022030212/58a0ce821a28ab6d018b6829/html5/thumbnails/15.jpg)
Financial Data(R$ million and % Net Revenues)
3Q15 3Q163Q15 3Q163Q15 3Q163Q15 3Q16
15
EBITDA Margin
(%)
Op. Exp. SG&A
(%)
Gross Margin
(%)
Gross Revenues
(R$ million)
3.3
2.4
7.77.4
10.5
9.6
1,040.6
1,010.4
![Page 16: Profarma - 3Q16 earnings release](https://reader031.fdocuments.us/reader031/viewer/2022030212/58a0ce821a28ab6d018b6829/html5/thumbnails/16.jpg)
![Page 17: Profarma - 3Q16 earnings release](https://reader031.fdocuments.us/reader031/viewer/2022030212/58a0ce821a28ab6d018b6829/html5/thumbnails/17.jpg)
17
Financial Data (*)
(R$ million and % Net Revenues)
3Q15 3Q163Q15 3Q163Q15 3Q163Q15 3Q16
EBITDA Margin
(%)
Op. Exp. SG&A
(%)
Gross Margin
(%)
Gross Revenues
(R$ million)
(*) Basis 100%
0.9
3.0
9.08.9
10.6
12.0
241.5
201.4
![Page 18: Profarma - 3Q16 earnings release](https://reader031.fdocuments.us/reader031/viewer/2022030212/58a0ce821a28ab6d018b6829/html5/thumbnails/18.jpg)
![Page 19: Profarma - 3Q16 earnings release](https://reader031.fdocuments.us/reader031/viewer/2022030212/58a0ce821a28ab6d018b6829/html5/thumbnails/19.jpg)
19(*) 3Q15 pro forma figures: 100% of Tamoio
Financial Data(R$ million and % Net Revenues)
3Q15* 3Q163Q15* 3Q163Q15* 3Q163Q15* 3Q16
EBITDA Margin
(%)
Op. Exp. SG&A
(%)
Gross Margin
(%)
Gross Revenues
(R$ million)
3.6
1.3
25.8
26.9
30.3
29.2
198.1
191.0
![Page 20: Profarma - 3Q16 earnings release](https://reader031.fdocuments.us/reader031/viewer/2022030212/58a0ce821a28ab6d018b6829/html5/thumbnails/20.jpg)
20
Total Sales Growth(%)
SSS Mature Stores(%)
Same Store Sales(%)
Monthly Average
Store's Sales (mature)(R$ thousand)
(*) 3Q15 pro forma figures: 100% of Tamoio
3Q15 3Q162Q16 3Q15 3Q162Q163Q15 3Q162Q16 3Q15 3Q162Q16
3.7%
10.5% 10.8 %
-6.8 p.p.
-7.0 p.p.
5.3%
2.5%
8.5%
-2.8 p.p.
-6.0 p.p.
6.0%
3.9%
11.1%
-2.1 p.p.
-7.2 p.p.
564.0589.7
550.2
2.5%
-4.4%
![Page 21: Profarma - 3Q16 earnings release](https://reader031.fdocuments.us/reader031/viewer/2022030212/58a0ce821a28ab6d018b6829/html5/thumbnails/21.jpg)
21
2 Opening
1 Close-downs
2 Reformulated
103 Mature
Average Ticket(R$)
# of Stores(units)
(*) 3Q15 pro forma figures: 100% of Tamoio
3Q15 3Q162Q163Q15 2Q16 3Q16
34,07
35,8335,82
5.2%
0.0%
128129
130
1.6%
0.8%
![Page 22: Profarma - 3Q16 earnings release](https://reader031.fdocuments.us/reader031/viewer/2022030212/58a0ce821a28ab6d018b6829/html5/thumbnails/22.jpg)
![Page 23: Profarma - 3Q16 earnings release](https://reader031.fdocuments.us/reader031/viewer/2022030212/58a0ce821a28ab6d018b6829/html5/thumbnails/23.jpg)
23
Company Analyst Telephone E-mail
Brasil Plural Guilherme Assis +55 (11) 3206 8285 [email protected]
BTG Pactual Rodrigo Gastim +55 (11) 3383-2468 [email protected]
BofA Merrill Lynch Roberto Otero +55 (11) 2188-4119 [email protected]
Eleven Financial Raul Grego Lemos +55 (11) 4302-3340 [email protected]
J.P. Morgan Joseph Giordano +55 (11) 4950-3020 [email protected]
Votorantim Paulo Prado +55 (11) 5171 5625 [email protected]
![Page 24: Profarma - 3Q16 earnings release](https://reader031.fdocuments.us/reader031/viewer/2022030212/58a0ce821a28ab6d018b6829/html5/thumbnails/24.jpg)
Max Fischer - CFO e IRO & Beatriz Diez - IRM
www.profarma.com.br/ir | Phone.: 55 (21) 4009-0276 | E-mail: [email protected]